Effect of the Biofield Energy Treated Test Formulation on Tissue Specific Biomarkers in Various Human Cells

Journal: SM Journal of Pharmacology and Therapeutics PDF  Web

Published: July 3, 2019 Volume: 5 Issue: 1

ISSN: 2574-2396

Authors: Jagdish Singh, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal and Snehasis Jana

Citation: Singh J, Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, et al. Effect of the Biofield Energy Treated Test Formulation on Tissue Specific Biomarkers in Various Human Cells. SM J Pharmac Ther. 2019; 5(1): 1021.

  • 15 Views
  • Downloads

Abstract

Dysfunction of vital organs are the main concern for human health. Therefore, it is necessary to homeostat the normal function of vital organs such as lungs, liver, brain, and heart for better health. The aim of this study was to evaluate the effect of the Consciousness Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Jagdish Singh, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the tested formulation was safe and non-toxic in nature in six different cells. The experimental groups like untreated medium (UT-Med) + Biofield Treated Test Item (BTTI), BT-Med + UT-TI, and BT-Med + BT-TI showed 190.5%, 56.3%, and 73.8% restoration of cell viability at 1μg/mL in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, BT-Med + UT-TI and BT-Med + BT-TI groups showed 98.8% and 79.1% restoration of cell viability at 10μg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 261.7%, 165.8%, and 167.8% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1, 1, and 10μg/mL, respectively compared to untreated. Alkaline phosphatase (ALP) level was significantly increased by 52.5% and 66.1% in the BT-Med + UT-TI group at 10 and 50μg/mL, respectively in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 101% and 170.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 50μg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 191.8% (at 0.01μg/mL) and 141.8% (10 μg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 88.1% (at 1μg/mL) and 44.9% (at 63μg/mL) in the BT-Med + UT-TI and UT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 19.6% and 13.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 25μg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 475.6% (at 0.1μg/mL), 311.9% (at 1μg/mL), 400.5% (at 10μg/mL) and 250.9% (at 63μg/mL) in the BT-Med + BT-TI group compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 185% and 285.8% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10μg/mL compared to the untreated in MG-63 cells. Utterly, these results suggest that Biofield Energy Treated test formulation significantly improved the relevant bones, heart, liver, lungs, and brain-related functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, pneumonia, asthma, emphysema, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

The study outcomes showed that the tested novel formulation was safe and non-toxic based on MTT cell viability assay in six tested cells. The treatment groups like UT-Med + BT-TI and BT-Med + BTTI showed 190.5% and 73.8% restoration of cell viability in human cardiac fibroblasts cells (HCF) compared to UT-Med + UT-TI group. Moreover, BT-Med + UT-TI and BT-Med + BT-TI groups showed 98.8% and 79.1% restoration of cell viability at 1μg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Besides, 261.7%, 165.8%, and 167.8% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + BT-TI group at 0.1, 1, and 10μg/mL, respectively compared to the untreated. Alkaline phosphatase (ALP) activity was significantly increased by 101% and 170.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 50μg/mL in human endometrial adenocarcinoma cells (Ishikawa). The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 191.8% (at 0.01μg/mL) and 141.8% (10μg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 44.9% (at 63μg/mL) and 88.1% (at 1μg/mL) in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 19.6% in the BT-Med + UT-TI group at 25μg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 475.6% (at 0.1μg/mL), 311.9% (at 1μg/mL), 400.5% (at 10μg/mL) and 250.9% (at 63μg/mL) in the BT-Med + BT-TI group compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 185% and 285% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10μg/mL compared to the untreated in MG-63 cells. In conclusion, The Biofield Energy Treatment significantly improved heart, liver, bones, neuronal, and lungs functional enzyme biomarkers and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte, and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, it can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (high blood pressure, stroke, congestive heart failure, peripheral artery disease, congenital heart disease, rheumatic heart disease, valvular heart disease, carditis, thromboembolic disease, and venous thrombosis, etc.), hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), and lungs disorders (Asthma, Chronic bronchitis, Emphysema, Cystic fibrosis, Pneumonia). Further, it could be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Ulcerative Colitis (UC), Dermatitis, Asthma, Irritable Bowel Syndrome (IBS), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Multiple Sclerosis, Aplastic Anemia, Hepatitis, Graves’ Disease, Dermatomyositis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Atherosclerosis, Systemic Lupus Erythematosus (SLE), stress, etc. to improve overall health and Quality of Life.